Study Summary
As a phase I clinical research，this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.
Want to learn more about this trial?
Request More InfoInterventions
CD70 CAR-T cellsBIOLOGICAL
Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
CD70 CAR-T cellsBIOLOGICAL
Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Henan Cancer Hospital | Zhengzhou | Henan | China |